Amprius Technologies reported a 126% increase in revenue to $34 million in Q2 and improved its gross margin to 27%. The company raised its 2026 revenue forecast for the second time this year, supported by new commercial wins including a $24 million drone order and a multi-year deal with Stark Future. Despite a more reasonable valuation at 11 times 2026 revenue, challenges remain in achieving sustainable profitability and cash flow conversion. The analyst maintains a Hold rating at $11, awaiting proof of margin expansion and improved cash flow before considering a Buy.
Valeo SE has announced it will exercise its option to redeem €750 million of its 5.375% bonds maturing in May 2027 early, with the redemption date set for August 24, 2026. This make-whole redemption means bondholders will receive a calculated amount ...
Valeo SE announced it will exercise its make-whole redemption option to redeem in full its €750 million 5.375% sustainability-linked bonds due May 2027. The redemption will occur on August 24, 2026, ahead of the original maturity date, with the redem...
Nxera Pharma announced a net profit of JPY 1,591 million (US$10.1 million) for Q2 2026, reversing a prior loss due to multiple milestone payments from partners like Neurocrine, AbbVie, and Lilly. The company progressed regulatory approvals and commer...
Between July 30 and August 5, 2026, Bekaert repurchased 50,500 of its own shares worth nearly €2 million as part of its ongoing €75 million buyback program, with all repurchased shares planned for cancellation. Additionally, under its liquidity agree...
Between July 30 and August 5, 2026, Bekaert repurchased 50,500 shares as part of its €75 million share buyback program, aiming to cancel all repurchased shares. The average price paid was €39.40 per share, totaling nearly €2 million. Additionally, un...
